Monday, June 24, 2024
AstriVax has commenced a Phase I clinical study to assess the safety and effectiveness of its prophylactic vaccines for yellow fever (AVX70120) and rabies (AVX70481) in healthy adults. This initial human trial, called SAFYR, aims to provide essential safety and immunogenicity data, which will be crucial for advancing AstriVax's therapies for chronic infections such as Hepatitis B and human papillomavirus (HPV).
The SAFYR study is being conducted at two leading vaccine trial sites in Belgium: the Centre for Vaccinology in Ghent and Vaccinopolis in Antwerp. The trial will involve nearly 100 healthy adults aged 18 to 40 to assess the safety and immune response generated by these vaccines. The results are expected to offer clinical validation for the AstriVax vaccine platform.
AstriVax, noted, “This trial showcases our innovative technology in a clinical proof-of-concept study. We use plasmids to deliver live-attenuated virus vectors with the target viral antigen, creating a self-amplifying mechanism that aims to produce strong and lasting immune responses with minimal doses.”
AstriVax's groundbreaking vaccines are expected to transform the fight against viral pathogens. They are designed for easy production, have minimal cold chain requirements, and are anticipated to trigger robust, long-lasting immune responses.
Currently, AstriVax is a clinical-stage company with a strong pipeline targeting viral infections and addressing urgent medical needs, such as chronic Hepatitis B, which affects over 250 million people, and HPV, a major cause of cervical cancer.
AstriVax, reflected, “Less than two years ago, we started with strong academic foundations and secured a €30 million seed round. In May 2023, we received a grant from Flanders Innovation & Entrepreneurship (VLAIO) to further advance our technology. I am incredibly grateful to my exceptional team for their dedication in shaping the company. We expect our chronic Hepatitis B immunotherapy to enter the clinical phase in 2025, marking another significant milestone for AstriVax.”
Source: globenewswire.com
